FDA Clearance Tracker · P810031-S065
Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)
Last checked: Nov 20, 2026Latest source record: Apr 29, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Apr 29, 2019
Approved
Time to decision
147 days
Received Dec 3, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P810031-S065
- Device name
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)
- Applicant location
- Irvine, CA
- Received
- Dec 3, 2018
- Decided
- Apr 29, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P810031
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for Healon GV® PRO, a modification of the Healon5 PRO OVD with the sodium hyaluronate concentration changed from 23 mg/mL to 18 mg/mL. The device, as modified, will be marketed under the trade name Sodium Hyaluronate Ophthalmic Viscoelastc Device (OVD), Healon GV® PRO and is indicated for use in anterior segment ophthalmic surgical procedures of the human eye. The Healon GV® PRO OVD is designed to create and maintain a deep anterior chamber which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. The Healon GV® PRO OVD can also be used to efficiently separate and control ocular issues. The Healon GV® PRO OVD is not designed to have any pharmacological effect.
Source documents
Other decisions for Johnson & Johnson Surgical Vision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TECNIS PureSee IOL, Model DEN00V TECNIS PureSee Toric II IOLs, Model DET150, DET225, DET300, DET375PMA supplement
P980040-S176 · Decided Mar 11, 2026 · 223 days after receipt · Panel Track
Device type: intraocular lens (HQL) · Ophthalmology
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.